Source comparison
CJC-1295 no DAC vs Tesamorelin + Ipamorelin Blend: Research Outcome Comparison
Peak GH Amplitude 8–12 ng/mL (single pulse) 15–22 ng/mL (synchronized dual pulse) 40–68% higher peak concentration with blend due to synergistic receptor activation Visceral Fat Reduction 8–12% reduction over 16 weeks 15–18% reduction over 12 weeks Blend achie
This comparison does not assign a generated winner or score.
- Peak GH Amplitude
- 8–12 ng/mL (single pulse)
- 15–22 ng/mL (synchronized dual pulse)
- 40–68% higher peak concentration with blend due to synergistic receptor activation
- Visceral Fat Reduction
- 8–12% reduction over 16 weeks
- 15–18% reduction over 12 weeks
- Blend achieves greater fat loss in shorter timeframe. Visceral adipocytes respond preferentially to sustained GH elevation
- Receptor Desensitization
- Observed after 5–7 days continuous dosing
- Minimal through 12+ weeks daily dosing
- Ghrelin pathway activation in blend prevents GHRH receptor downregulation
- Dosing Frequency
- Every 2–3 days (rest intervals required)
- Daily (no mandatory rest intervals)
- Blend allows more consistent GH elevation without receptor fatigue
- Lean Mass Retention
- 2–4% increase over 12 weeks
- 3–6% increase over 12 weeks
- Both protocols support anabolism, but blend's higher GH amplitude drives greater nitrogen retention
- IGF-1 Elevation
- 35–50% above baseline
- 55–75% above baseline
- Higher sustained IGF-1 with blend correlates with improved recovery markers and protein synthesis rates
- Professional Assessment
- Effective single-pathway option for moderate GH stimulation. Limited by receptor desensitization requiring rest intervals
- Superior dual-pathway protocol delivering higher-amplitude, longer-duration GH pulses with sustained efficacy. Ideal for visceral fat reduction and lean mass optimization
- The table makes the distinction clear: CJC-1295 no DAC is not ineffective. It's mechanistically limited. The blend doesn't just work better by degree. It works through an entirely different mechanism that avoids the primary constraint limiting single-agent GHRH protocols. When researchers compare cjc-1295 no dac vs tesamorelin + ipamorelin blend outcomes in controlled settings, the difference isn't preference. It's measurable receptor biology.